Regulation
Valar Labs hits US first with breakthrough designation for AI bladder cancer test
Valar Labs received FDA Breakthrough Device designation for Vesta Bladder Risk Stratify Dx, an AI-powered diagnostic tool that analyzes stained pathology slides to generate risk assessments for bladder cancer patients. The designation is the company's first in the US market.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network